Ask AI
ProCE Banner Activity

Eine globale Initiative zur Verbesserung der Versorgung bei rezidivierter/refraktärer CLL

PDF

An diesem Expertengespräch nehmen 3 international anerkannte CLL-Spezialisten teil, die die dringendsten und häufigsten klinischen Fragen ansprechen, die in der modernen Ära der zielgerichteten Therapien auftauchen. Ihre praktischen Erkenntnisse bieten Orientierung zu Sequenzierung der Therapie, Resistenzeinschätzung, Biomarker-Nutzung und Herausforderungen im realen Management bei rezidivierter/refraktärer CLL

Released: February 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Lymphoma Coalition.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme LLC.

Lilly

Merck Sharp & Dohme, LLC

Partners

Lymphoma Coalition

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of global hematologists, oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals caring for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences to optimize clinical outcomes for patients with relapsed/refractory CLL/SLL, considering available evidence, local expert recommendations, regional guidelines, and disease/patient factors

  • Appraise emerging clinical evidence for novel BTK-targeted therapies and the clinical implications for management of relapsed/refractory CLL/SLL

  • Assess resistance mutations in patients with relapsed/refractory CLL/SLL who progressed on or following covalent BTK inhibitor therapy

  • Implement multidisciplinary team processes to mitigate the risk of treatment- and disease-related complications in patients with relapsed/refractory CLL/SLL

  • Apply shared decision-making strategies to support patient quality of life and engagement in care for relapsed/refractory CLL/SLL

Disclosure

Primary Author

Stéphane Lepretre

Henri Becquerel Cancer Center
Department of Hematology
Member of FILO, LYSA
Rouen, France

Stéphane Lepretre, MD, has no relevant financial relationships to disclose.

Stephan Stilgenbauer, MD

Medical Director Comprehensive Cancer Center Ulm (CCCU)
Head Early Clinical Trials Unit (ECTU)
Head Division of CLL Department of Internal Medicine III
Comprehensive Cancer Center Ulm (CCCU)
University of Medical Center Ulm
Ulm, Germany

Stephen Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson; researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson.

Alessandra Tedeschi, MD

Consultant in Hematology
Niguarda Cancer Center
ASST GOM Niguarda
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly.